Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
By Ciara Linnane
Chronic autoimmune disease mostly affects women
Biogen Inc.'s stock was slightly lower Tuesday, shedding early gains made after the company and Belgian partner UCB announced positive results in a late-stage trial of a treatment for the chronic autoimmune disease lupus.
The Phase 3 trial sought to evaluate dapirolizumab pegol plus standard of care in people living with moderate-to-severe lupus and met its primary goal of improvement after 48 weeks compared with placebo in addition to standard of care.
The trial also met secondary endpoints measuring disease activity and flares. UCB (BE:UCB) and Biogen (BIIB) said they would initiate a second Phase 3 trial in 2024. Patients in the first study will continue to be tracked in a long-term, open-label study. Details of the outstanding Phase 3 trial will be presented at a coming medical conference, said Biogen and UCB.
"These positive results with dapirolizumab pegol represent encouraging progress in the development of medicines that can improve the lives of those living with lupus, an area that remains one of high unmet medical need and where women are disproportionately affected," said Fiona du Monceau, head of patient evidence at Brussels-based UCB.
Lupus is a painful disease that can affect multiple organ systems with periods of illness or flares that alternate with periods of inactivity. Symptoms can include rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures or psychosis.
The illness is associated with a greater risk of death from causes such as infection and cardiovascular disease.
About 90% of people living with lupus are women and most start to show symptoms around the ages of 15 to 55.
Biogen's stock has fallen 24.7% in the year to date, while the SPDR S&P Biotech ETF XBI has gained 9.8% and the S&P 500 SPX has gained 19.9%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-24-24 1104ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally